AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial

RecruitingPhase 2Ages 40 Years - anyAllLondon Health Sciences Centre Research Institute โ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The objectives of this study are to determine the feasibility of conducting a full-scale randomized control trial comparing the efficacy of tamsulosin compared to placebo in reducing post-operative urinary retention in people undergoing elective thoracic surgery.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria ( 2 or more of the following risk factors): * Male Sex * Age greater than or equal to 40 years * History of Diabetes Mellitus * Prior pelvic irradiation * Use of indwelling Thoracic Epidural analgesia * Prior history of urinary retention AND International Prostate Specific Score greater than or equal to 1. Exclusion Criteria: * Active treatment of Benign Prostatic Hyperplasia (BPH) * Hypersensitivity or allergy to tamsulosin HCL * Active treatment with tamsulosin or other alpha-blocker or uses of tamsulosin/ other alpha-blocker within 3 weeks of enrollment date * Active urinary tract infection * History of urological disorder specified as urethral stricture, BPH, bladder or prostate malignancy. * History of urological surgery (Transurethral resection of the Prostate, Transurethral resection of the Bladder, Bladder suspension, prostatectomy) * Underlying neurological disorders resulting in impaired bladder function * Any known contraindication to the use of tamsulosin HCL * Nursing/ Breastfeeding women * Use of intraoperative bladder catheter * patients for whom cataract and/or glaucoma surgery is scheduled. * patients on strong inhibitors of CYP3A4 (e.g., ketoconazole), on moderate inhibitors of CYP3A4 (e.g., erythromycin), on strong (e.g. paroxetine), on moderate (e.g., terbinafine) inhibitors of CYP2D6 or in patients known to be CYP2D6 poor metabolizers. * patients with a serious or life-threatening sulfa allergy * patients with severe hepatic insufficiency * patients with severe renal impairment (creatinine clearance of \<10 mL/min) * patients with a serious or life-threatening sulfa allergy
๐Ÿ’Š

What it tests

  • Tamsulosin Hydrochloride
  • Placebo
๐Ÿ“

Where

1 site
London Health Sciences Centre
London, Canada
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy